1.
Eur Urol Focus
; 4(5): 636-638, 2018 09.
Artículo
en Inglés
| MEDLINE
| ID: mdl-30197041
RESUMEN
The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5mo. Final results will be available in 2019.